RE:RE:Stockhouse ArticleLaserStock29 wrote
Bunge wrote: 5 Promising Stocks under $5
One stock the article lists is IMV
IMV Inc. (TSX: IMV) - Headquartered in Halifax, Nova Scotia, IMV is a clinical stage biopharmaceutical company that is pioneering a novel class of immunotherapies called DPX-Survivac, which it believes could generate solid tumour regressions. After entering into a research collaboration with The Wistar Institute in Philadelphia, IMV reported preliminary data from its
Phase 2 study in multiple solid tumours, showing positive results from treatment. IMV is well funded, reporting cash and cash equivalents of $21.4 million (CAD) and working capital of $21.2 million last December, compared with $14.9 million and $12.2 million, respectively back in December 31, 2018.
Has only 50M shares so take the $4.60 and divide by 4 and you have potential $1.15 for TLT with solid preliminary data for our PH2.
I remember a while back bencro saying 10 patients at 6 months was worth 500m
Were' gonna have 5 at their 6 month by May or early into it. so ill take 250m
160m is Mackie .80 from 200m OS
160m is Morningstar .54 from 300m Full diluted OS
160m is Roget 2014 Cambridge on Phase 1 Big Pharma (now + inflation to 2020)
Claridge posted 200m deal with 10x multiple to 2b.
I posted the link of the 2-10b for the biotech deals 2b = $7 USD on the low end.
All these projections dont account for any preclinical work or Phase 1 of GBM or Lung.. i.e. the projections cannot factor in the 'expansion' of our technology as that's how those nice 'business excel sheet estimates ala 'conservatism' works. Very true LaserStock29 its extremely difficult to estimate stock value on an unknown factor which is the next cancer indication to be entering into PH1B, each cancer has an estimated value to the network of pharmaceutical & insurance industries. What we do know is depending on how many patients in this Bladder trial out of the total are CR then that will give a possible outcome in future trials whether its brain, lung, colon, etc. Once this company succeeds in the 2nd cancer with higher CR then current treatments or competitive trials the stock will no longer adhere to your conservative estimated earnings .... thereby proofing your thought. Looking for primary data to support or exceed PH1 will be well received .... jmo